Skip to main content
. Author manuscript; available in PMC: 2020 Aug 19.
Published in final edited form as: Nature. 2020 Feb 19;579(7797):130–135. doi: 10.1038/s41586-020-2015-4

Figure 2: The IL33-ILC2 axis activates tissue-specific cancer immunity.

Figure 2:

Tumor weight, volumes, and survival of Il33+/+ and Il33−/− orthotopic (a) or subcutaneous (b) PDAC mice. (c) Frequency of all (left) and IFN-γ producing (right) CD8+ T cells in orthotopic Il33+/+and Il33−/−PDAC tumors. (d) Tumor weight in T cell–depleted Il33+/+and Il33−/− orthotopic PDAC mice. (e) Frequency of tumor rejection and tumor weight in Il33+/+and Il33−/− orthotopic and subcutaneous KPC-OVA PDAC mice. (f) Experimental design (left), frequency of tumor rejection (middle), and tumor weight (right) of KPC-OVA PDAC tumors in iCOS-T mice with intact or depleted ILC2s. (g) Frequency of OVA-specific CD8+ T cells in draining lymph nodes of orthotopic KPC-OVA PDAC iCOS-T mice with intact or depleted ILC2s. Data were collected at 14 days (a, c, d), 28 days (b), 42 days (e), and 8 (f, g) days post implantation. Horizontal bars mark medians, error bars mark s.e.m. Data were pooled from ≥2 independent experiments with n≥4/group; n and data points denote individual mice analyzed separately. P values were determined by two-tailed Mann-Whitney test (a-g), two-sided log-rank test (a, b, survival curves), two-way ANOVA with Sidak’s multiple comparison test (a, b, tumor volumes), and Chi-square test (e, f % rejection).